Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2Breast 2Lymphoid 1Genitourinary 1Endocrine 1Dermatologic 1

Conditions

Lymphoma, Mantle-Cell 1

Interventions

Rituximab 689Cyclophosphamide 614Vincristine 285Etoposide 272Doxorubicin 271Cytarabine 230Prednisone 228Methotrexate 221fludarabine phosphate 189Filgrastim 187Dexamethasone 180fludarabine 175Lenalidomide 165Radiotherapy 128Melphalan 127Peripheral Blood Stem Cell Transplantation 123Busulfan 118Bendamustine Hydrochloride 116Granulocyte Colony-Stimulating Factor 113Bortezomib 112ibrutinib 111Mycophenolic Acid 110venetoclax 106Whole-Body Irradiation 106Tacrolimus 105obinutuzumab 104Gemcitabine 92zanubrutinib 81Specimen Handling 80Cyclosporine 76

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Complementary Therapies × Lymphoid × Clear all
NCT00003502 2013-07-10

Antineoplaston Therapy in Treating Patients With Mantle Cell Lymphoma

National Cancer Institute (NCI)

Phase 2 Withdrawn
Lymphoid

Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡